Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
| Autor: | Dariusz Jawniak, Aneta Goracy, Agnieszka Szymczyk, Elzbieta Drab-Urbanek, Małgorzata Kowal, Blanca Ibanez, Aleksandra Nowaczyńska, Marek Hus, Arkadiusz Macheta, Olga Jankowska-Lecka, Sylwia Chocholska, Monika Podhorecka |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Adult Male Chemokine Chronic lymphocytic leukemia T cell T regulatory cells B-cell receptor T-Lymphocytes Regulatory 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Immune system Piperidines T-Lymphocyte Subsets ibrutinib hemic and lymphatic diseases medicine Bruton's tyrosine kinase Humans Aged Cell Proliferation biology business.industry Adenine T-cells breakpoint cluster region Middle Aged medicine.disease Prognosis Leukemia Lymphocytic Chronic B-Cell cytokines 030104 developmental biology medicine.anatomical_structure Pyrimidines Treatment Outcome Oncology chemistry 030220 oncology & carcinogenesis Ibrutinib Immunology biology.protein Pyrazoles chronic lymphocytic leukemia Female business Signal Transduction Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Monika Podhorecka 1 , Aneta Goracy 1 , Agnieszka Szymczyk 1 , Malgorzata Kowal 1 , Blanca Ibanez 1 , Olga Jankowska-Lecka 1 , Arkadiusz Macheta 1 , Aleksandra Nowaczynska 1 , Elzbieta Drab-Urbanek 1 , Sylwia Chocholska 1 , Dariusz Jawniak 1 and Marek Hus 1 1 Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland Correspondence to: Monika Podhorecka, email: monika.podhorecka@onet.pl Keywords: chronic lymphocytic leukemia, cytokines, ibrutinib, T-cells, T regulatory cells Received: January 16, 2017 Accepted: February 08, 2017 Published: March 13, 2017 ABSTRACT B cell receptor (BCR) stimulation signal plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL), and kinase inhibitors directed toward the BCR pathway are now the promising anti-leukemic drugs. Ibrutinib, a Bruton tyrosine kinase inhibitor, demonstrates promising clinical activity in CLL. It is reported that ibrutinib, additionally to directly targeting leukemic cells, also inhibits the interactions of these cells with T cells, macrophages and accessory cells. Assessment of these mechanisms is important because of their non -direct anti-leukemic effects and to identify possible side effects connected with long-term drug administration. The aim of this study was to assess the in vivo effects of ibrutinib on T-cell subpopulations and cytokine network in CLL. The analysis was performed on a group of 19 patients during first month of ibrutinib therapy. The standard multicolor flow cytometry and cytometric bead array methods were used for assessment of T-cell subsets and cytokines/chemokines, respectively. The data obtained indicates that Ibrutinib treatment results in changes in T-cell subpopulations and cytokine network in CLL patients. Particularly, a significant reduction of T regulatory cells in peripheral blood was observed. By targeting these populations of T cells Ibrutinib can stimulate rejection of tumor cells by the immune system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|